Navigation Links
Protein predicts Gleevec resistance in gastrointestinal tumors
Date:5/15/2008

ease IGF-1R activity induced the death of tumor cells.

According to Godwin and his colleagues, their studies are the first to reveal that the development of wild type GISTs could be related to abnormal expression of IGF-1R.

IGF-1R overproduction seems to be a common factor in a number of different cancers, and there are several IGF-1R-targeted therapeutic agents in development and in clinical trials that might also be effective against GISTs, Godwin says. As is often the case with targeted therapies, we need to find the right patient for the drug as much as we need to find the right drug for the disease.

Godwin and his colleagues will soon publish the full results of their studies and have begun investigating the possibility of testing for IGF-1R in clinical trials at Fox Chase.


'/>"/>

Contact: Greg Lester
gregory.lester@fccc.edu
215-728-2753
Fox Chase Cancer Center
Source:Eurekalert

0

GOOD

Page: 1 2

Related medicine news :

1. Carnegie Mellon engineering researchers automate analysis of protein patterns
2. Virus mimics human protein to hijack cell division machinery
3. Naturally-occuring protein may be effective in limiting heart attack injury and restoring function
4. Scientists identify interacting proteins key to melanoma development, treatment
5. Double duty: Loss of protective heart failure protein causes high blood pressure
6. Protein May Trigger Colon Cancer
7. Study in 7,000 men and women ties obesity, inflammatory proteins to heart failure risk
8. First atomic-level look at a protein that causes brain disease
9. OHSU Cancer Institute researcher identifies protein that helps predict prostate cancer survival
10. Detour(R) Unveils Snack Size Protein Bar
11. Genome analysis reveals new protein associated with breast cancer progression
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/25/2008)..., July 25 /PRNewswire/ -- BeaconEquity.com announc...ng news today., Investors can view all of the dai...conEquity.com/m , Today,s Trade Alerts include: D...rook Pharmaceuticals Inc. (Nasdaq: MBRK ), NovaMe... ), Affymetrix Inc. (Nasdaq: AFFX ) and,Abaxis In...
(Date:7/25/2008)...Relationship Based on Significant Improvements in ... MDdatacor, Inc., a leader in health,care quality ...s, today,announced it has entered into a long-term...ort Wellmark,s Collaboration on Quality(SM) Incent...tion between Wellmark and,primary care clinicians ...
(Date:7/25/2008)...AD, Calif., July 25 /PRNewswire/ -- AutoGenomics, ...ion statement on Form S-1 with the,Securities and ...al public,offering of shares of its common stock. ..., all of which are expected to be offered by,AutoG...g, have not yet been,determined., J.P. Morgan Sec...
(Date:7/25/2008)... Whether you are an Olympian, Profe... there are Five Things You Need to Know about Hydr...C. Spine and Sports Center , ...- America,s premier athletes are heading to Beijin...g and sacrifice in the hopes of capturing an Olymp...
Breaking Medicine News(10 mins):Health News:BeaconEquity.com Issues Technical Trade Alerts on Healthcare/Pharmaceutical Stocks: DUSA, MBRK, NOVA, ADLR, AFFX, ABAX 2Health News:BeaconEquity.com Issues Technical Trade Alerts on Healthcare/Pharmaceutical Stocks: DUSA, MBRK, NOVA, ADLR, AFFX, ABAX 3Health News:MDdatacor Extends Contract with Wellmark, Inc. 2Health News:MDdatacor Extends Contract with Wellmark, Inc. 3Health News:AutoGenomics, Inc. Files Registration Statement for Initial Public Offering 2Health News:Hydration Will Be Key For Beijing Bound Olympians, What Every Athlete Must Know 2Health News:Hydration Will Be Key For Beijing Bound Olympians, What Every Athlete Must Know 3Health News:Hydration Will Be Key For Beijing Bound Olympians, What Every Athlete Must Know 4Health News:Hydration Will Be Key For Beijing Bound Olympians, What Every Athlete Must Know 5
...y increase a person’s risk of developing dementia ...e effect.// In a recent study conducted, researche...n 20 years. They found those who were obese in mid...dementia later in life. Also, patients who had hig...
...s toll on active baby boomers. Arthritis followed ...//for many of the 78 million middle-aged Americans... ahead. Michael Baroli is finally back on his feet... directing. His glamour photography business depen...
...cancer diagnosed among men in the United States --...e several // treatment options, but new research s...ogether. Doctors hope that the drug -- finasteri...ng prostate cancer. In smaller doses, it’s commonl...
... a way to diagnose melancholic depression using an.../ levels of certain substances in the brain. Melan...arked by insomnia, loss of appetite, and loss of p...evels of the inhibitory transmitter GABA and high ...
Other Medicine News:
(Date:7/23/2008)...re/ -- The following was,released by the U.S. Depa...ber Smith, and Members of the Committee.,Thank you...ppeared before this Committee almost six months ag...alented and dedicated professionals,at the Justice...come to,appreciate that much more deeply their ser...
(Date:7/23/2008)...-- Dendreon Corporation,(Nasdaq: DNDN ) today ann...ring Committee (IDMC) to review in October 2008 th... the Company,s Phase 3 IMPACT (IMmunotherapy,for P...902B) clinical trial,of PROVENGE(R) (sipuleucel-T)... cellular immunotherapy for the treatment of advan...
(Date:7/22/2008)...in Medical, a leading innovator,of physiological m...tered,the clinical testing phase with its breakthr...ion. Today,s most common application for this,tech...l blood oxygenation,in the brain -- cerebral oxime...oing clinical study at the,Duke University Medical...
(Date:7/22/2008)...a Exhibits Excellent Drug-Like ...tiation of Phase II Clinical Trials -, RESEARCH T... BioPharma,Inc., a clinical stage company develop...diseases of the central nervous system, today anno...M) into Phase II trials for the,treatment of depre...
Breaking Medicine Technology:Prepared Remarks of Attorney General Michael B. Mukasey Before the House Judiciary Committee 2Prepared Remarks of Attorney General Michael B. Mukasey Before the House Judiciary Committee 3Dendreon Expects Interim Data Analysis for Phase 3 PROVENGE IMPACT Trial in October 2Dendreon Expects Interim Data Analysis for Phase 3 PROVENGE IMPACT Trial in October 3Dendreon Expects Interim Data Analysis for Phase 3 PROVENGE IMPACT Trial in October 4Nonin Medical Inc. Announces Entry Into the Cerebral Oximeter Market 2CeNeRx BioPharma Finalizes Plans to Initiate Phase II Trials for Its Novel Antidepressant Agent Tyrima(TM) Using Innovative Brain Imaging Study 2CeNeRx BioPharma Finalizes Plans to Initiate Phase II Trials for Its Novel Antidepressant Agent Tyrima(TM) Using Innovative Brain Imaging Study 3CeNeRx BioPharma Finalizes Plans to Initiate Phase II Trials for Its Novel Antidepressant Agent Tyrima(TM) Using Innovative Brain Imaging Study 4Nicotine addiction slashed in test of new cigarette smoking strategy 6279 1Nicotine addiction slashed in test of new cigarette smoking strategy 6279 2Nicotine addiction slashed in test of new cigarette smoking strategy 6279 3Synaptics SecurePad 28TM 29 Selected as CES Innovations 2008 Design and Engineering Award Honoree 1208 1Synaptics SecurePad 28TM 29 Selected as CES Innovations 2008 Design and Engineering Award Honoree 1208 2Synaptics SecurePad 28TM 29 Selected as CES Innovations 2008 Design and Engineering Award Honoree 1208 3Plastic Surgery Complications and Deaths are Rare Despite Highly Publicized Death of Donda West 6273 1Plastic Surgery Complications and Deaths are Rare Despite Highly Publicized Death of Donda West 6273 2Plastic Surgery Complications and Deaths are Rare Despite Highly Publicized Death of Donda West 6273 3Fortune 500 Executive Elected to AMA Board of Trustees 6267 1Fortune 500 Executive Elected to AMA Board of Trustees 6267 2
...%; mso-hyphenate: none">,BUDAPEST, Hungary, June, ...ands of patients with cancer from suffering,unnece...gress of,the European Association for Palliative C...ted whether this first in class novel,formulation ...duration of effect, mirroring the breakthrough pai...
...IMPAX Laboratories,Inc. (OTC:IPXL) today announce...company,s compound, IPX054, a combined immediate-,...oduct to be,marketed as VADOVA(TM), were presented...onal Congress of Parkinson,s Disease and,Movement ... poster,presentations will be available in the Inv...
Other Medicine Technology:Trial Results with Intranasal Fentanyl Hold Promise for Treatment,of Breakthrough Pain in Cancer 2Trial Results with Intranasal Fentanyl Hold Promise for Treatment,of Breakthrough Pain in Cancer 3Trial Results with Intranasal Fentanyl Hold Promise for Treatment,of Breakthrough Pain in Cancer 4Trial Results with Intranasal Fentanyl Hold Promise for Treatment,of Breakthrough Pain in Cancer 5Trial Results with Intranasal Fentanyl Hold Promise for Treatment,of Breakthrough Pain in Cancer 6IMPAX Presents at Movement Disorder Society's 11th International,Congress of Parkinson's Disease and Movement Disorders 2IMPAX Presents at Movement Disorder Society's 11th International,Congress of Parkinson's Disease and Movement Disorders 3IMPAX Presents at Movement Disorder Society's 11th International,Congress of Parkinson's Disease and Movement Disorders 4
Aegis CheckPoint is an automated, wireless, computerized remote temperature monitoring, recording, logging and alert system for refrigerator, freezer, incubator and water bath to replace chart record
This requiring no water for use, it provides convenient, long-lasting hand hygiene to physically clean hands when routine hand washing is either not an option or is not convenient. Hibistat allows yo
BioSoft alcohol gel hand antiseptic with soothing moisturizers is a fast-acting, broad-spectrum antimicrobial solution. BioSoft alcohol gel hand antiseptic applies easily, requires no rinsing and dri
Exidine® 2% CHG Brushless Surgical Scrub offers exceptional persistence and broad-spectrum antimicrobial activity.
Medicine Products: